As we have noted, Medical Marijuana Inc (OTCMKTS:MJNA) has an extremely weak track record in terms of dilution and effectively robbing its shareholders by every strategy in the book over the years. Remember, this stock has been a publicly traded issue for well over a decade, but is still on the pink sheets with no auditing of financial data, and has authorized 5 billion shares. Yes, you read that right. Five billion shares. And you were wondering why a CBD predication was down 15% since the announcement of the 2018 Farm Bill.
To make matters more interesting, the company just announced that its subsidiary HempMeds Brasil hosted its second Cannabinoid Medicine course on February 1, 2019, at the HempMeds Brasil office in São Paulo. According to the release, “The objective of the course, which was attended by doctors of many specialties, was to help educate on how cannabis interacts with the human body, the different treatment possibilities using cannabinoids and how cannabidiol (CBD) has the potential to help improve the wellbeing of Brazilians. The class was taught by Dr. Joaquim Daniel, Dr. Paula Vinha, Dr. Ailane Araujo, Cannabis Regulation Specialist Ricardo Handro, HempMeds Brasil Director of Medical Affairs Dr. Junior Gibelli, HempMeds Institutional Relations Director Norberto Fischer, and HempMeds Vice President Caroline Heinz.”
Medical Marijuana Inc (OTCMKTS:MJNA) casts itself as an investment holding company that operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high-value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries.
MJNA’s subsidiary, Kannaway, LLC, is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products
MJNA licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry. It engages in the research and development of cannabinoid-based pharmaceuticals; and marketing and distribution of cannabidiol hemp oil-based products.
In addition, MJNA provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics; and consulting and securities services to businesses and individuals in the legal cannabis industry. Further, it focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products, sportswear and more.”
According to company materials, “Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value.”
Find out when $MJNA reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, MJNA just announced that its subsidiary HempMeds Brasil hosted its second Cannabinoid Medicine course on February 1, 2019, at the HempMeds Brasil office in São Paulo.
Recent action has seen 9% added to share values of the stock over the past week of action. Moreover, the company has seen interest climb, with an increase in recent trading volume of 14% above its longer-run average levels.
“The event was a great success – we had many doctors show genuine interest in the work that we are doing and we were able to take a deep dive into why CBD needs to be recognized as a part of the next wave of healthcare in Brazil,” said HempMeds Brasil Vice President Caroline Heinz. “We hope to further develop our ongoing relationship with Brazilian healthcare professionals.”
At this time, carrying a capital value in the market of $306.3M, MJNA has a significant war chest ($4.8M) of cash on the books, which is balanced by about $4M in total current liabilities. One should also note that debt has been growing over recent quarters. MJNA is pulling in trailing 12-month revenues of $51.6M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 116.2%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $MJNA stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $MJNA, either long or short, and we have not been compensated for this article.